University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 3C-09-2

A Multi-Center, Open-Label, Randomized, Phase II Study to Evaluate the Efficacy and Safety of NKTR-102 (PEG-Irinotecan) versus Irinotecan in Patients with Second-Line, Irinotecan-Naïve, KRAS-Mutant, Colorectal Cancer with Metastatic or Locally Advanced Disease.

Type: Treatment
Phase: Phase II
Status: Not Open (Closed)
Treatments: Chemotherapy: Systemic
Randomized: Yes
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Heinz Josef Lenz, M.D.
Other Trial Staff:  Ramona Lujan, R.N., Carol Jones, R.N., Taison Tran, D.M., Daisy Sosa, D.M., Catherine Ticong, R.N.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.